Cardamyst: First Self-Administered Antiarrhythmic Nasal Spray, US FDA (Dec 2025)

 

                                                 Paroxysmal Supraventricular Tachycardia 

Etripamil is a short-acting L-type calcium channel blocker developed for self-treatment of paroxysmal supraventricular tachycardia (PSVT).

Researchers designed etripamil as a verapamil-like molecule but with:

• faster metabolism

• intranasal delivery

• minimal systemic exposure

                                

 

 

 

 

 

Mechanism Of Action

 First Self-Administered Anti arrhythmic Nasal Spray  

 

US FDA (Dec 2025) 

 

Etripamil blocks L-type calcium channels in the AV node, which:

• Slows AV nodal conduction

• Interrupts re-entry circuits

• Restores normal sinus rhythm

   

   
   

   

   

   

   

  Snapshot